CUDR as biomarker for cancer progression and therapeutic response

Abstract

Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy.

1 . An isolated nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2.  
     
     
         2 . The isolated nucleic acid of  claim 1 , wherein said nucleic acid has a sequence of SEQ ID NO: 1.  
     
     
         3 . An isolated polypeptide having an amino acid sequence of SEQ ID No: 2.  
     
     
         4 . An antibody binding specifically to a polypeptide having an amino acid sequence of SEQ ID NO: 2.  
     
     
         5 . A pharmaceutical composition for treating a tumor comprising an effective amount of an antibody binding specifically to a polypeptide having an amino acid sequence of SEQ ID NO: 2, or a nucleic acid having an antisense oligonucleotide sequence of SEQ ID No: 1 or a fragment thereof, and a pharmaceutically acceptable carrier, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer.  
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         7 . A kit for diagnosing a tumor or evaluating the treatment outcome of an anticancer agent in a subject, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer, comprising: 
 a pair of primers for amplification or a probe for hybridization of cDNA of an nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2 in a biological sample from the subject; and    an instructional material for use of the primers or the probe to determine the presence or the absence of the cDNA in the biological sample.    
     
     
         8 . The kit of  claim 7 , wherein the nucleic acid has a sequence of SEQ ID NO: 1.  
     
     
         9 . The kit of  claim 7 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         10 . The kit of  claim 8 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         11 . The kit of  claim 7 , wherein the biological sample is selected from the group consisting of a serum, a plasma, and a tissue.  
     
     
         12 . A kit for diagnosing a tumor or evaluating the treatment outcome of an anticancer agent in a subject, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer, comprising: 
 an antibody binding specifically to a polypeptide having an amino acid sequence of SEQ ID NO: 2 in a biological sample from the subject; and    an instructional material for use of the antibody to determine the presence or the absence of the polypeptide in the biological sample.    
     
     
         13 . The kit of  claim 12 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         14 . The kit of  claim 12 , wherein the biological sample is selected from the group consisting of a serum, a plasma, and a tissue.  
     
     
         15 . The kit of  claim 13 , wherein the biological sample is selected from the group consisting of a serum, a plasma, and a tissue.  
     
     
         16 . A method for diagnosing a subject suffering from or suspected of suffering from a tumor, or for evaluating the treatment outcome of an anticancer agent in a subject suffering from a tumor, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer, comprising: 
 providing a biological sample from the subject; and    detecting the cDNA of a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2 in the sample,    wherein the presence of the cDNA in the sample indicates the subject is suffering from a tumor or having a drug resistance against the anticancer agent.    
     
     
         17 . The method of  claim 16 , wherein the nucleic acid has a sequence of SEQ ID NO: 1  
     
     
         18 . The method of  claim 16 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         19 . The method of  claim 17 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         20 . The method of  claim 16 , wherein the biological sample is selected from the group consisting of a serum, a plasma, and a tissue.  
     
     
         21 . A method for diagnosing a subject suffering from or suspected of suffering from a tumor, or for evaluating the treatment outcome of an anticancer agent in a subject suffering from a tumor, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer, comprising: 
 providing a biological sample from the subject; and    detecting a polypeptide having an amino acid sequence of SEQ ID NO: 2 in the sample,    wherein the presence of the polypeptide in the sample indicates the subject is suffering from a tumor or having a drug resistance against the anticancer agent.    
     
     
         22 . The method of  claim 21 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.  
     
     
         23 . The method of  claim 21 , wherein the biological sample is selected from the group consisting of serum, plasma, and a tissue sample.  
     
     
         24 . A method for treating a tumor in a subject, comprising administrating to the subject an effective amount of an antibody binding specifically to a polypeptide having an amino acid sequence of SEQ ID NO: 2, or a nucleic acid having an antisense oligonucleotide sequence of SEQ ID No: 1 or a fragment thereof, with the proviso that the mammalian tumor is not an estrogen receptor alpha positive breast cancer.  
     
     
         25 . The method according to  claim 24 , wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, cervical cancer, colon cancer and estrogen receptor alpha negative breast cancer.  
     
     
         26 . A method for cloning a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2 in-frame into a vector comprising: 
 amplifying a full-length cDNA of the nucleic acid; and    cloning the full-length cDNA into a suitable vector.    
     
     
         27 . The method of  claim 26 , wherein the vector is pENTR-SD/D-TOPO.  
     
     
         28 . An expression vector having a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2.  
     
     
         29 . The vector of  claim 28  including pcDNA-DEST40.  
     
     
         30 . An in vitro model of acquiring drug resistance in cancer cells or cell lines prepared by transfecting a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2 into the cells.